Company chart and information is provided by TradingView based on 15-minute-delayed data.
Tenax Therapeutics, Inc., is a specialty pharmaceutical company focused on identifying, developing, and commercializing products that address cardiovascular and pulmonary diseases with high unmet medical need. The Company has a world-class scientific advisory team including recognized global experts in pulmonary hypertension. The Company owns North American rights to develop and commercialize levosimendan and has recently released topline data regarding their Phase 2 clinical trial for the use of levosimendan in the treatment of Pulmonary Hypertension associated with Heart Failure and preserved Ejection Fraction (PH-HFpEF). For more information, visit www.tenaxthera.com.
| Website: | www.tenaxthera.com |
| Email: | jesse@sternir.com |
| Main Phone: | +1 919 855-2100 |
| Address: | ONE Copley Parkway |
| Address 2: | Suite 490 |
| State: | NC |
| City / Town: | Morrisville |
| Country: | US |
| Postal Code: | 27560 |
| Exchange: | NSC |
| CEO: | Anthony A. DiTonno |
| Employees: | 10 |
| NAICS: | Research and Development in Biotechnology (except Nanobiotechnology)(541714) |
| Last Price N/A | Change $ N/A | Change % N/A | Tick N/A |
| Bid N/A | Bid Size N/A | Ask N/A | Ask Size N/A |
| Open N/A | High N/A | Low N/A | Prev Close N/A |
| Last Trade | Volume N/A | 52 Wk Hi N/A | 52 Wk Low N/A |
| Market Cap N/A | Ex-Div Date N/A | Div Rate N/A | Yield N/A |
| Shares N/A | EPS (TTM) N/A | PE Ratio N/A | Exchange N/A |
© 2022 Equities News | Equities.com, Inc.
* All dates and time are being displayed in Eastern Standard Time (EST).
